Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension

OBJECTIVE: To evaluate whether eculizumab helps patients with anti-acetylcholine receptor-positive (AChR+) refractory generalized myasthenia gravis (gMG) achieve the Myasthenia Gravis Foundation of America (MGFA) post-intervention status of minimal manifestations (MM), we assessed patients' status throughout REGAIN (Safety and Efficacy of Eculizumab in AChR+ Refractory Generalized Myasthenia Gravis) and its open-label extension. METHODS: Patients who completed the REGAIN randomized controlled trial and continued into the open-label extension were included in this tertiary endpoint analysis. Patients were assessed for the MGFA post-intervention status of improved, unchanged, worse, MM, and pharmacologic remission at defined time points during REGAIN and through week 130 of the open-label study. RESULTS: A total of 117 patients completed REGAIN and continued into the open-label study (eculizumab/eculizumab: 56; placebo/eculizumab: 61). At week 26 of REGAIN, more eculizumab-treated patients than placebo-treated patients achieved a status of improved (60.7% vs 41.7%) or MM (25.0% vs 13.3%; common OR: 2.3; 95% CI: 1.1-4.5). After 130 weeks of eculizumab treatment, 88.0% of patients achieved improved status and 57.3% of patients achieved MM status. The safety profile of eculizumab was consistent with its known profile and no new safety signals were detected. CONCLUSION: Eculizumab led to rapid and sustained achievement of MM in patients with AChR+ refractory gMG. These findings support the use of eculizumab in this previously difficult-to-treat patient population. CLINICALTRIALSGOV IDENTIFIER: REGAIN, NCT01997229; REGAIN open-label extension, NCT02301624. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that, after 26 weeks of eculizumab treatment, 25.0% of adults with AChR+ refractory gMG achieved MM, compared with 13.3% who received placebo

Minimal Symptom Expression' in Patients With Acetylcholine Receptor Antibody-Positive Refractory Generalized Myasthenia Gravis Treated With Eculizumab

The efficacy and tolerability of eculizumab were assessed in REGAIN, a 26-week, phase 3, randomized, double-blind, placebo-controlled study in anti-acetylcholine receptor antibody-positive (AChR+) refractory generalized myasthenia gravis (gMG), and its open-label extension

Mortality from gastrointestinal congenital anomalies at 264 hospitals in 74 low-income, middle-income, and high-income countries: a multicentre, international, prospective cohort study

Background: Congenital anomalies are the fifth leading cause of mortality in children younger than 5 years globally. Many gastrointestinal congenital anomalies are fatal without timely access to neonatal surgical care, but few studies have been done on these conditions in low-income and middle-income countries (LMICs). We compared outcomes of the seven most common gastrointestinal congenital anomalies in low-income, middle-income, and high-income countries globally, and identified factors associated with mortality. // Methods: We did a multicentre, international prospective cohort study of patients younger than 16 years, presenting to hospital for the first time with oesophageal atresia, congenital diaphragmatic hernia, intestinal atresia, gastroschisis, exomphalos, anorectal malformation, and Hirschsprung's disease. Recruitment was of consecutive patients for a minimum of 1 month between October, 2018, and April, 2019. We collected data on patient demographics, clinical status, interventions, and outcomes using the REDCap platform. Patients were followed up for 30 days after primary intervention, or 30 days after admission if they did not receive an intervention. The primary outcome was all-cause, in-hospital mortality for all conditions combined and each condition individually, stratified by country income status. We did a complete case analysis. // Findings: We included 3849 patients with 3975 study conditions (560 with oesophageal atresia, 448 with congenital diaphragmatic hernia, 681 with intestinal atresia, 453 with gastroschisis, 325 with exomphalos, 991 with anorectal malformation, and 517 with Hirschsprung's disease) from 264 hospitals (89 in high-income countries, 166 in middle-income countries, and nine in low-income countries) in 74 countries. Of the 3849 patients, 2231 (58·0%) were male. Median gestational age at birth was 38 weeks (IQR 36–39) and median bodyweight at presentation was 2·8 kg (2·3–3·3). Mortality among all patients was 37 (39·8%) of 93 in low-income countries, 583 (20·4%) of 2860 in middle-income countries, and 50 (5·6%) of 896 in high-income countries (p<0·0001 between all country income groups). Gastroschisis had the greatest difference in mortality between country income strata (nine [90·0%] of ten in low-income countries, 97 [31·9%] of 304 in middle-income countries, and two [1·4%] of 139 in high-income countries; p≤0·0001 between all country income groups). Factors significantly associated with higher mortality for all patients combined included country income status (low-income vs high-income countries, risk ratio 2·78 [95% CI 1·88–4·11], p<0·0001; middle-income vs high-income countries, 2·11 [1·59–2·79], p<0·0001), sepsis at presentation (1·20 [1·04–1·40], p=0·016), higher American Society of Anesthesiologists (ASA) score at primary intervention (ASA 4–5 vs ASA 1–2, 1·82 [1·40–2·35], p<0·0001; ASA 3 vs ASA 1–2, 1·58, [1·30–1·92], p<0·0001]), surgical safety checklist not used (1·39 [1·02–1·90], p=0·035), and ventilation or parenteral nutrition unavailable when needed (ventilation 1·96, [1·41–2·71], p=0·0001; parenteral nutrition 1·35, [1·05–1·74], p=0·018). Administration of parenteral nutrition (0·61, [0·47–0·79], p=0·0002) and use of a peripherally inserted central catheter (0·65 [0·50–0·86], p=0·0024) or percutaneous central line (0·69 [0·48–1·00], p=0·049) were associated with lower mortality. // Interpretation: Unacceptable differences in mortality exist for gastrointestinal congenital anomalies between low-income, middle-income, and high-income countries. Improving access to quality neonatal surgical care in LMICs will be vital to achieve Sustainable Development Goal 3.2 of ending preventable deaths in neonates and children younger than 5 years by 2030

Efficacy Of Rotary Ni-Ti Retreatment Systems In Root Canals Filled With A New Warm Vertical Compaction Technique

The aim of this study was to compare the efficacy of Mtwo, Pro Taper retreatment files and Hedstrom files for the retreatment of root canals filled with Bee Fill 2 in 1 and cold lateral compaction techniques. 63 single-rooted human teeth were prepared with Mtwo rotary files to size 35/.04 and assigned into three groups (n=21/group). (1) Bee Fill 2 in1/2Seal, (2) Bee Fill 2 in 1/AH26 and (3) laterally-compacted gutta-percha/AH26. The specimens were subgrouped according to the file system used to remove root fillings (n=7/subgroup): 1. Mtwo retreatment file, 2. Pro Taper retreatment file, 3. Hedstrom file. Roots were split longitudinally and photographed. The time required for removal of root canal fillings and the areas of residual root filling materials were compared statistically (p<0.05). The maximum amount of remnant was observed in the Mtwo group for removal of BeeFill 2 in1/AH26. ProTaper retreatment files required less time to remove root filling material than Mtwo retreatment files and Hedstrom files (p<0.05). Among the tested removal systems. ProTaper retreatment files may offer the best efficiency-speed combination.WoSScopu

Benchmarking Deep Learning Frameworks with FPGA-suitable Models on a Traffic Sign Dataset

We benchmark several widely used deep-learning frameworks for performing deep-learning-related automotive tasks (e.g., traffic sign recognition) that need to achieve realtime and high accuracy results with limited resources available on embedded platforms such as FPGAs. In our benchmarks, we use various input image sizes on models that are suitable for FPGA deployment, and investigate the training speed and inference accuracy of selected frameworks for these different sizes on a popular traffic sign recognition dataset. We report results by running the frameworks solely on the CPU as well as by turning on GPU acceleration. We also provide optimizations we apply to fine-tune the performance of the frameworks. We discover that Neon and MXNet deliver the best training speed and inference accuracy in general for all our test cases, while Tensorflow is always among the frameworks with the highest inference accuracies. We also observe that on the particular dataset we tested on (i.e., GTSRB), the image size of the region of interest does not necessarily affect the inference accuracy, and that using deep models, e.g., ResNet-32, which have longer training times, might not provide improvements to inference accuracy

Intrathecal IgM production correlates with more severe disease course in multiple sclerosis: Clinical and MRI results

12th International Congress of Neuroimmunology (ISNI) -- NOV 09-13, 2014 -- Mainz, GERMANYWOS: 000345192100029

Fast Deformable Registration on the GPU: A CUDA Implementation of Demons

In the medical imaging field, we need fast deformable registration methods especially in intra-operative settings characterized by their time-critical applications. Image registration studies which are based on Graphics Processing Units (GPUs) provide fast implementations. However, only a small number of these GPU-based studies concentrate on deformable registration. We implemented Demons, a widely used deformable image registration algorithm, on NVIDIA's Quadro FX 5600 GPU with the Compute Unified Device Architecture (CUDA) programming environment. Using our code, we registered 3D CT lung images of patients. Our results show that we achieved the fastest runtime among the available GPU-based Demons implementations. Additionally, regardless of the given dataset size, we provided a factor of 55 speedup over an optimized CPU-based implementation. Hence, this study addresses the need for on-line deformable registration methods in intra-operative settings by providing the fastest and most scalable Demons implementation available to date. In addition, it provides an implementation of a deformable registration algorithm on a GPU, an understudied type of registration in the general-purpose computation on graphics processors (GPGPU) community